JP2008536815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536815A5 JP2008536815A5 JP2008501999A JP2008501999A JP2008536815A5 JP 2008536815 A5 JP2008536815 A5 JP 2008536815A5 JP 2008501999 A JP2008501999 A JP 2008501999A JP 2008501999 A JP2008501999 A JP 2008501999A JP 2008536815 A5 JP2008536815 A5 JP 2008536815A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- thioether bridge
- population
- cysteine residue
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 229960001521 motavizumab Drugs 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical group OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66172405P | 2005-03-14 | 2005-03-14 | |
| US69913805P | 2005-07-13 | 2005-07-13 | |
| PCT/US2006/009311 WO2006099481A2 (en) | 2005-03-14 | 2006-03-14 | Macromolecules comprising a thioether cross-link |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008536815A JP2008536815A (ja) | 2008-09-11 |
| JP2008536815A5 true JP2008536815A5 (enExample) | 2009-05-21 |
Family
ID=36992404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501999A Abandoned JP2008536815A (ja) | 2005-03-14 | 2006-03-14 | チオエーテル架橋を含む巨大分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7786273B2 (enExample) |
| EP (1) | EP1858911A4 (enExample) |
| JP (1) | JP2008536815A (enExample) |
| AU (1) | AU2006223002A1 (enExample) |
| CA (1) | CA2600844A1 (enExample) |
| WO (1) | WO2006099481A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG170799A1 (en) * | 2006-03-28 | 2011-05-30 | Biogen Idec Inc | Anti-igf-ir antibodies and uses thereof |
| CN101842116A (zh) * | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 结合igf-1r多个表位的组合物 |
| CN101842117A (zh) * | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 抗igf-1r抗体及其用途 |
| BRPI0816094A2 (pt) | 2007-08-30 | 2015-03-03 | Daiichi Sankyo Co Ltd | Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo. |
| KR20180102215A (ko) | 2007-11-27 | 2018-09-14 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도 |
| WO2009126304A1 (en) * | 2008-04-11 | 2009-10-15 | Biogen Idec Ma Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
| CN104854125A (zh) * | 2012-11-05 | 2015-08-19 | 米迪缪尼有限公司 | 在不存在全能核酸酶的情况下分离synagis*的方法 |
| EP3212510B1 (en) * | 2014-10-31 | 2020-12-09 | Medlmmune, LLC | Manufacturing method of a degassed composition |
| AU2017222402B2 (en) * | 2016-02-25 | 2024-02-01 | The Binding Site Group Limited | Antibodies |
| GB201603291D0 (en) | 2016-02-25 | 2016-04-13 | Binding Site Group The Ltd | Antibodies |
| EP3974447A3 (en) | 2016-10-21 | 2022-09-07 | Adimab, LLC | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| SG11201903287PA (en) | 2016-10-21 | 2019-05-30 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| GB201708262D0 (en) | 2017-05-23 | 2017-07-05 | Binding Site Group Ltd | Assay for plasma cell associated disease |
| CN108017717B (zh) * | 2018-01-24 | 2019-08-16 | 首都医科大学宣武医院 | 一种用于体外高效定向扩增的嵌合抗原受体及其应用 |
| GB202007047D0 (en) | 2020-05-13 | 2020-06-24 | Binding Site Group Ltd | Mass spectrometry controls |
| EP4295158A1 (en) * | 2021-02-19 | 2023-12-27 | Waters Technologies Corporation | Methods for peptide mapping of adeno-associated virus (aav) proteins |
| WO2025104604A1 (en) | 2023-11-14 | 2025-05-22 | Janssen Pharmaceuticals, Inc. | Anti-respiratory syncytial virus antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US5091542A (en) | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
| JP3407260B2 (ja) * | 1991-08-09 | 2003-05-19 | コルベツク，ヴインフリート | ランチオニン架橋ペプチド |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| CA2370043A1 (en) * | 1999-04-23 | 2000-11-02 | Mitsubishi Chemical Corporation | Liposome bonded with antibody and polyalkylene glycol |
| US20060123504A1 (en) * | 2004-12-07 | 2006-06-08 | Avigenics, Inc. | Methods of producing polyclonal antibodies |
| US20060286548A1 (en) * | 2005-06-16 | 2006-12-21 | Gregory Liposky | Method of making recombinant human antibodies for use in biosensor technology |
-
2006
- 2006-03-14 AU AU2006223002A patent/AU2006223002A1/en not_active Abandoned
- 2006-03-14 WO PCT/US2006/009311 patent/WO2006099481A2/en not_active Ceased
- 2006-03-14 US US11/375,810 patent/US7786273B2/en active Active
- 2006-03-14 US US11/908,601 patent/US20090030187A1/en not_active Abandoned
- 2006-03-14 CA CA002600844A patent/CA2600844A1/en not_active Abandoned
- 2006-03-14 EP EP06738376A patent/EP1858911A4/en not_active Withdrawn
- 2006-03-14 JP JP2008501999A patent/JP2008536815A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008536815A5 (enExample) | ||
| HRP20230338T1 (hr) | Anti-sars-cov-2-spike-glikoprotein antitijela i fragmenti za vezivanje antigena | |
| HRP20090517T1 (hr) | Protutijela na interleukin-10 | |
| JP2024038003A5 (enExample) | ||
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| JP2020508655A5 (enExample) | ||
| UA86605C2 (ru) | Антитело, которое содержит вариант исходного человеческого fс-участка | |
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| WO2005056600B1 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| MX2009012319A (es) | Polipeptidos que se unen a receptores fc con funciones efectoras modificadas. | |
| HUP9802401A2 (hu) | Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására | |
| JP2020524510A5 (enExample) | ||
| ATE469176T1 (de) | Modifizierter anti-tnf antikörper | |
| RU2015151505A (ru) | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) | |
| JP2008529529A5 (enExample) | ||
| JP2005510246A5 (enExample) | ||
| JP2016531546A5 (enExample) | ||
| JP2015510875A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| JP2016529213A5 (enExample) | ||
| TWI857999B (zh) | 截斷的多價多元體 | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| JPWO2021081365A5 (enExample) | ||
| JPWO2020071554A5 (enExample) |